Glenmark Pharma’s US arm gets USFDA approval for Ursodiol tablets

13 Jul 2011 Evaluate

Glenmark Generics’ (GGL) United States (US) subsidiary -- Glenmark Generics Inc., (GGI) -- has been granted final approval for its Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (USFDA) for Ursodiol tablets USP, their generic version of Urso 250 and Urso Forte tablets by Axcan.

Ursodiol tablets are available in 250mg and 500mg strengths and are indicated for the treatment of patients with primary biliary cirrhosis (PBC). Total market sales achieved for the Ursodiol tablets were $60 million.

Glenmark’s current portfolio consists of 70 products authorized for distribution in the US marketplace and 40 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

GGL is a subsidiary of Glenmark Pharmaceuticals and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries.

Glenmark Pharma Share Price

1369.65 -52.20 (-3.67%)
25-Apr-2025 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.35
Dr. Reddys Lab 1170.55
Cipla 1524.75
Lupin 2048.40
Zydus Lifesciences 865.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...